Navigation Links
MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock
Date:8/1/2012

MOUNTAIN VIEW, Calif., Aug. 1, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the pricing of an underwritten public offering of 3,880,598 shares of its common stock at a price of $13.40 per share to the public. All of the shares are being sold by MAP Pharmaceuticals. The gross proceeds to MAP Pharmaceuticals from this offering are expected to be approximately $52 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by MAP Pharmaceuticals. The offering is expected to close on or about August 6, 2012, subject to the satisfaction of customary closing conditions.  MAP Pharmaceuticals has also granted the underwriters a 30-day option to purchase an additional 582,088 shares of common stock.  MAP Pharmaceuticals intends to use the proceeds from the offering for general corporate purposes and commercialization activities for LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. 

BofA Merrill Lynch is acting as the sole book-running manager for the offering. 

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. The offering is being made by means of a prospectus and related prospectus supplement. Copies of the prospectus supplement may be obtained, when available, from the offices of BofA Merrill Lynch, 222 Broadway, 7th Floor, New York, NY 10038, Attn: Prospectus Department, or email dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to our expectations regarding the completion of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in the United States or internationally. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the public offering, MAP Pharmaceuticals and our business can be found under the heading "Risk Factors" in our most recent Form 10-Q filed with the SEC, in other filings that we periodically make with the SEC, and in the prospectus supplement related to the offering to be filed with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: Christopher Y. Chai, Sr. Vice President and Chief Financial Officer of MAP Pharmaceuticals, Inc., (650) 386-3107; or media, Lisa Borland, (650) 386-3122, lborland@mappharma.com.

 

 


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
2. Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC
3. Avion Pharmaceuticals, LLC., Launches Prenate Mini
4. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
6. Acella Pharmaceuticals, LLC, files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration for Topical Corticosteroids Lotion
7. Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
9. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
10. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
11. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 ... Enterprises Limited, anuncia el nombramiento de Stuart ... una plataforma de servicios integrados completa para su ... un cargo clave en el crecimiento y ejecución ... será responsable de impulsar todas las actividades de ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... March 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" ... specialty pharmaceutical company, is pleased to announce that ... approval from the U.S. Food and Drug Administration ... ("ANDA") for tetrabenazine tablets in the 12.5 mg ... is a generic equivalent of the branded product ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 2017 , ... The Boulevard is honored to host Shriners and Masons Children’s ... located in the Main West Entrance of The Boulevard (in front of JCPenney). ... necessary and each child with a parent or guardian will be photographed for free ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... News Advisory/Interview ... Choice has helped score a major victory in Europe for public health and the ... , Based on rigorous scientific research and the overwhelming support of European citizens, ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: ... A Legacy” is the creation of published author, Desiree M Webb, a registered nurse, ... She has been happily married to her husband, Paul, for over twenty-nine years. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden ... innovative patient - centric payment system, to expand its focus on patient care ... patient financial experience. , “At Ogden Clinic, we are working to become ...
(Date:3/23/2017)... ... ... Trainer”: an electrifying and suspenseful gunslinger novel with a twist. “The Trainer” is ... an enthusiasm for action and adventure stories. , Published by Christian Faith ... at the thirty-three notches that lined the edges of the wooden grip plates of ...
Breaking Medicine News(10 mins):